CASSAVA SCIENCES INC (SAVA)

Cassava Sciences Plummets 85% After Embattled Alzheimer's Drug Flops

The company tested simufilam in patients with mild-to-moderate Alzheimer's disease.

Which stocks are moving before the opening bell on Monday?

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in...

Cassava Sciences to Hold Corporate Update on November 25th

Webcast planned for Monday, November 25th at 8:00 AM ET

Cassava Sciences to Hold Corporate Update on November 25th

Webcast planned for Monday, November 25th at 8:00 AM ET...

January 2025 Options Now Available For Cassava Sciences (SAVA)

Noteworthy Monday Option Activity: SQ, CAVA, SAVA

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates...

Noteworthy Friday Option Activity: SPHR, FIVN, SAVA

Cassava Sciences Reports Q3 2024 Financial and Operating Results

Cassava Sciences Reports Q3 2024 Financial and Operating Results

Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash Equivalents at September 30, 2024....

Notable Friday Option Activity: SQ, WERN, SAVA

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Conference call and webcast to begin at 8:30 AM ET

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Conference call and webcast to begin at 8:30 AM ET...

Notable Thursday Option Activity: STNG, SAVA, SQ

Noteworthy Friday Option Activity: X, SAVA, CRM

Notable Thursday Option Activity: SAVA, KTB, ACLX

Why Cassava Sciences Stock Dived by Almost 11% Today

Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive.

Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims

Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of an Alzheimer’s drug trial.

Cassava Sciences Resolves SEC Investigation

Cassava Sciences Resolves SEC Investigation

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on...